Status:
COMPLETED
Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Urgent Isolated CABG Using MiECC in Patients With Recent Acute Myocardial Infarction
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Heart Attack
Cardioplegia Solution Adverse Reaction
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to compare the two cardioplegia solutions (blood cardioplegia by means of MPS ® vs. Cardioplexol ®) regarding perioperative outcome and with special attention to cardiac mark...
Eligibility Criteria
Inclusion
- Patients who underwent a CABG using MPS® or Cardioplexol ®
- Heart attack less than 7 days before surgery
Exclusion
- use of other cardioplegia solution than Cardioplexol ® or MPS®
- other inventions than CABG
- explicit will of the patient that his data may not be used
- denied general consent
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
307 Patients enrolled
Trial Details
Trial ID
NCT04309994
Start Date
February 1 2010
End Date
January 1 2020
Last Update
March 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiac Surgery Clinic University Hospital Basel
Basel, Switzerland, 4031